RINVOQ – a once-daily oral selective JAK inhibitor1
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.1
RINVOQ + MTX demonstrated significantly greater remission rates* vs placebo + MTX and adalimumab + MTX1,2
| • | Remission rate:* 29% for RINVOQ + MTX vs 6% with placebo + MTX (primary endpoint)† and 18% for adalimumab + MTX‡ at Week 12 (P≤0.001 for both comparisons) |
See remission data
RINVOQ + MTX was superior to
adalimumab + MTX at Week 12 on ACR50, pain, and HAQ-DI2
• | ACR50 response rate: 45% for RINVOQ + MTX vs 15% with placebo + MTX and 29% for adalimumab + MTX§ at Week 12 (P≤0.001 for both comparisons) |
• | Patient-reported pain: –32.1 change from baseline (VAS) for RINVOQ + MTX vs –15.7 with placebo + MTX and –25.6 for adalimumab + MTX§ at Week 12 (P≤0.001 for both comparisons) |
• | Physical function: –0.60 change from baseline in HAQ-DI for RINVOQ + MTX vs –0.28 with placebo + MTX|| and –0.49 for adalimumab + MTX§ at Week 12 (P≤0.001 vs placebo + MTX, P≤0.01 vs adalimumab + MTX) |
See efficacy data
RINVOQ’s safety in RA has been established across 5 robust Phase 3 clinical trials involving more than 4,000 patients1
See safety profile
Rinvoq Prescribing Information
For full information please see Rinvoq prescribing information Full prescribing information can be received from Abbvie Biopharmaceuticals Ltd. Israel at 4 Hacharash Street, Hod Hasharon 4524075. Tel: 09-7909600, Fax: 09-790960
1. RINVOQ Prescribing Information, March 2023.
2. Fleischmann R, Pangan AL, Song IH, et al. Upadacitnib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, double-blind, randomized controlled trial [published online July 9, 2019]. Arthritis Rheumatol 2019;71:1788-1800. doi:10.1002/art.41032
IL-RNQR-230007. Date of preparation: May 2023.